Skip to main navigation

    Library: Global (English)  Life Sciences - 27
    Next >>





    EY- Cash on prescription Cash on prescription - 2014
    (pdf, 793.57 KB)
    04 Jul, 2014 Global

    Pharma saw improved working capital performance in 2013, but progress has not been sufficient to reverse deterioration of previous years. Our report explores.

    EY - Beyond borders 2014 cover Beyond borders unlocking value
    (pdf, 2.51 MB)
    23 Jun, 2014 Global

    EY - Beyond borders unlocking value

    EY - Biotechnology in europe cover Biotechnology in Europe
    (pdf, 2,74 MB)
    12 Jun, 2014 Global

    EY - Biotechnology in europe

    EY - Progressions: Navigating the payer landscape Progressions 2014: Navigating the payer landscape
    (pdf, 1,99 MB)
    06 May, 2014 Global

    For pharmaceutical companies, a fragmented and rapidly changing payer universe poses challenges and raises some key questions. Our pharma report explores.

    EY - Commercial excellence in pharma 3.0 cover Commercial excellence in pharma 3.0
    (pdf, 1,33 MB)
    12 Feb, 2014 Global

    EY - Commercial excellence in pharma 3.0

    Progressions 2010: Pharma 3.0 GPI_report_2010_Progressions_Pharma_3
    (pdf, 4,13 MB)
    15 Jan, 2014 Global

    Progressions: Pharma 3.0

    EY - Worldwide research and development incentive guide EY-Worldwide-RD-incentives-reference-guide-2013-2014
    (pdf, 6,67 MB)
    02 Jan, 2014 Global

    Research and development (R&D) incentives have grown in number and importance in recent years. Read our latest guide detailing R&D incentive regimes in 34 countries.

    EY - Managing regulatory and legal risk in the digital world - publication cover Managing regulatory and legal risk in the digital world
    (pdf, 8.95 MB)
    14 Oct, 2013 Global

    As the availability of health information via digital channels grows, life sciences companies face increasing regulatory and legal risks. What steps should be taken now?

    EY - Cash on prescription 2013 Cash on prescription 2013
    (pdf, 435.06 KB)
    14 Aug, 2013 Global

    The 14 leading pharma companies have up to US$40 billion tied up unnecessarily in working capital. What strategies can help companies increase efficiency?

    Biopharma in an era of elusive growth
    (pdf, 977.59 KB)
    03 Jul, 2013 Global

    Have investor-friendly capital allocation and new competitors upended the world order in M&A? Find out how the biopharma sector is facing this challenge.

    Next >>
    Back to top